We are interested in the molecular mechanisms that cause
leukemias and lymphomas. The scope of our research projects ranges from
the elucidation of an epigenetic suppressor mechanism to the
characteriziation of leukemogenic signal transduction pathways in the
- Deborah and Tara join the lab. They will work on B-cell receptor signaling and mobility in CLL. Welcome!
- Christine nails the hypomethylation of NFATC1, a major effector in
the B-cell receptor signaling cascade that is so central to the
pathomechanism of chronic lymphocytic leukemia. This explains at least
in part why this pathway is so strongly active. Excellent work!
- We write a commentary on the first comprehensive description of the
different resistancies that can develop in CLL patients that are
treated with the new magic bullet, ibrutinib, a BTK inhibtor: "unwanted
- Michael joins the lab. His expertise is on CRISPR, and he will take a
closer look at signaling and chromatin of CLL. A real asset for the
lab, very welcome!